Literature DB >> 1111876

Effect of I,25-dihydroxycholecalciferol in renal osteodystrophy.

D S Silverberg, K B Bettcher, J B Dossetor, T R Overton, M F Holick, H F DeLuca.   

Abstract

A 23-year-old man with medullary cystic disease had been undergoing hemodialysis for 5 years and had become confined to a wheelchair because of renal osteodystrophy. He was treated with 125-dihydroxycholecalciferol, 2.0 mug (later 1.0 mug) three times a week, administered by way of the venous end of the dialysis machine. Within 1 month bone pain lessened and his ability to stand and walk improved. By 3 months he was walking short distances and by 5 months, long distances. Calcium balance was near zero before treatment and was strongly positive during treatment. Bone mineral content in the lower femur, measured by photon absorptiometry, increased at a rate of 32.2% per year. In contrast, 26 other patients on long-term hemodialysis had a mean loss of bone mineral content of 14.0% per year. Radiographs taken during treatment showed a decrease in subperiosteal bone resorption and healing of a pseudofracture. A significant decrease in the mean serum alkaline phosphatase value was noted during treatment, but no significant changes in mean serum calcium or phosphorus values were seen.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1111876      PMCID: PMC1956416     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  7 in total

Review 1.  The kidney as an endocrine organ for the production of 1,25-dihydroxyvitamin D 3 , a calcium-mobilizing hormone.

Authors:  H F DeLuca
Journal:  N Engl J Med       Date:  1973-08-16       Impact factor: 91.245

Review 2.  Vitamin D metabolism. Recent advances.

Authors:  T C Stamp
Journal:  Arch Dis Child       Date:  1973-01       Impact factor: 3.791

3.  Role of 1,25-dihydroxycholecalciferol in calcification of bone and maintenance of serum calcium concentration in the rat.

Authors:  Y Tanaka; H Frank; H F DeLuca
Journal:  J Nutr       Date:  1972-12       Impact factor: 4.798

4.  Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.

Authors:  R G Henderson; R G Russell; J G Ledingham; R Smith; D O Oliver; R J Walton; D G Small; C Preston; G T Warner
Journal:  Lancet       Date:  1974-03-09       Impact factor: 79.321

5.  Can renal bone disease be prevented?

Authors:  S Shaldon
Journal:  Proc Eur Dial Transplant Assoc       Date:  1973

6.  The stimulation of 1,25-dihydroxycholecalciferol metabolism in vitamin D-deficient rats by 1,25-dihydroxycholecalciferol treatment.

Authors:  C A Frolik; H F DeLuca
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

7.  1,25 Dihydroxy-vitamin D3 in normal man and patients with renal failure.

Authors:  A S Brickman; J W Coburn; S G Massry; A W Norman
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

  7 in total
  5 in total

1.  Excretion of inhibitors of calcification in urine Part II. Findings in patients with chronic renal failure.

Authors:  D G Oreopoulos; D Walker; D J Akriotis; D A Roncari; H Husdan; A Symvoulidis; G A Deveber; A Rapoport; D B Reid
Journal:  Can Med Assoc J       Date:  1975-04-05       Impact factor: 8.262

2.  Treatment of bone disease with dihydrotachysterol in patients undergoing long-term hemodialysis.

Authors:  P E Cordy
Journal:  Can Med Assoc J       Date:  1977-10-08       Impact factor: 8.262

3.  1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy.

Authors:  A M Pierides; H A Ellis; H Dellagrammatikas; J E Scott; A W Norman
Journal:  Arch Dis Child       Date:  1977-06       Impact factor: 3.791

4.  [Renal osteodystrophy in children. Therapy with 1,25-dihydroxy-cholechalciferol (author's transl)].

Authors:  M Bulla; G Delling; G Benz-Bohm; G J Stock; A Sánchez de Reutter; R Ziegler; H Lühmann; M Severin; E Kalbitzer; C Manegold
Journal:  Klin Wochenschr       Date:  1980-05-16

5.  Treatment of renal osteodystrophy with 1,25-dihydroxycholecalciferol.

Authors:  C Velentzas; D G Oreopoulos; A Pierratos; H E Meema; S Rabinovich; H Meindok; H Husdan; T M Murray; R Ogilvie; A Katirtzoglou
Journal:  Can Med Assoc J       Date:  1981-03-01       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.